The global APIs (Active Pharmaceutical Ingredients) market is estimated at approximately USD 210 billion in 2024 and is projected to grow at a CAGR of 6.3% through 2032. This growth is driven by rising demand for generic drugs, increasing prevalence of chronic and lifestyle diseases, and the surge in biologics APIs and specialty pharmaceuticals. The API value chain encompasses raw material suppliers, contract API manufacturers, and fully integrated pharmaceutical companies. Leading players, including Lonza Group, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Pfizer, are investing in process optimization, novel API development, and strategic acquisitions to strengthen their market positions.
APIs overview
Published by MMR Statistics Research Team, Updated